MedPath

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Phase 3
Active, not recruiting
Conditions
Unresectable HER2-Positive Breast Carcinoma
Stage III Breast Cancer AJCC v7
Stage IV Breast Cancer AJCC v6 and v7
Metastatic Breast Adenocarcinoma
Metastatic HER2-Positive Breast Carcinoma
Recurrent Breast Adenocarcinoma
Recurrent HER2-Positive Breast Carcinoma
Unresectable Breast Carcinoma
Interventions
Procedure: Biopsy
Procedure: Bone Scan
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Other: Placebo Administration
Other: Quality-of-Life Assessment
Registration Number
NCT03199885
Lead Sponsor
National Cancer Institute (NCI)
Brief Summary

This randomized phase III trial studies how well paclitaxel, trastuzumab, and pertuzumab with or without atezolizumab works in treating patients with breast cancer that has spread to other parts of the body (metastatic). Chemotherapy drugs, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab is a form of "targeted therapy" because it works by attaching itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body's immune system. Monoclonal antibodies, such as pertuzumab, may interfere with the ability of cancer cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving paclitaxel, trastuzumab, and pertuzumab with or without atezolizumab may kill more tumor cells.

\*NOTE: This study has a central confirmation step. The purpose of this step is to confirm by central testing that the patient's tumor has specific receptors. If the patient meets all the study requirements, the patient will join the study and begin therapy for breast cancer while the tumor is being tested.

Detailed Description

PRIMARY OBJECTIVE:

I. To determine whether the addition of atezolizumab to a regimen of pertuzumab and trastuzumab combined with a taxane (paclitaxel or docetaxel) will improve the progression-free survival (PFS), assessed by investigator using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, relative to the addition of a placebo to a regimen of pertuzumab and trastuzumab combined with a taxane (paclitaxel or docetaxel) in patients with newly documented HER2-positive measurable metastatic breast cancer.

SECONDARY OBJECTIVES:

I. To determine whether the addition of atezolizumab to a regimen of pertuzumab and trastuzumab combined with a taxane (paclitaxel or docetaxel) will improve the overall survival (OS) relative to the addition of placebo to a regimen of pertuzumab and trastuzumab, combined with a taxane (paclitaxel or docetaxel).

II. To determine whether the addition of atezolizumab to a regimen of pertuzumab and trastuzumab combined with a taxane (paclitaxel or docetaxel) will improve the overall objective response (OR) in the cohort of patients randomized 6 months or more prior to study accrual closure assessed by investigator using RECIST 1.1 criteria, relative to the addition of placebo to a regimen of pertuzumab and trastuzumab combined with a taxane (paclitaxel or docetaxel).

III. To determine the immune-related toxicity profile of the two treatment regimens.

IV. To determine the cardiac safety profile of the two treatment regimens.

EXPLORATORY OBJECTIVES:

I. To determine whether the addition of atezolizumab to a regimen of pertuzumab and trastuzumab combined with a taxane (paclitaxel or docetaxel) will decrease the incidence of subsequent brain metastases in patients without known brain metastases at study entry relative to the addition of a placebo to a regimen of pertuzumab and trastuzumab combined with a taxane (paclitaxel or docetaxel).

II. To determine the utility of PD-L1 immunohistochemistry (IHC) staining as a predictive and prognostic biomarker associated with clinical response, as assessed by investigator using RECIST 1.1 criteria, to atezolizumab in combination with trastuzumab and pertuzumab combined with a taxane (paclitaxel or docetaxel).

III. To identify potential biomarkers that can predict benefit from the addition of atezolizumab in patients with newly documented HER2-positive measurable metastatic breast cancer treated with a regimen of pertuzumab and trastuzumab combined with a taxane (paclitaxel or docetaxel).

IV. To explore the toxicity profile of the two treatment regimens using patient-reported symptomatic adverse events in addition to standard adverse event reports.

V. To determine the feasibility and added value of frequent assessment of toxicity using Patient Reported Outcomes (PRO)-Common Terminology Criteria for Adverse Events (CTCAE) with electronic(e)PRO reporting.

VI. To explore whether the addition of atezolizumab to a regimen of pertuzumab and trastuzumab combined with a taxane (paclitaxel or docetaxel) will contribute to increased patient-reported fatigue in comparison to the addition of placebo to a regimen of pertuzumab and trastuzumab combined with a taxane (paclitaxel or docetaxel).

OUTLINE:

STEP 1: Patients receive pertuzumab intravenously (IV) over 30-60 minutes on days 1 and 22, trastuzumab IV over 30-90 minutes on days 1 and 22, and paclitaxel IV over 60 minutes on days 1, 8, 15, 22, 29, and 36 or docetaxel IV over 60 minutes on days 1 and 22. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients may undergo a biopsy at baseline. Patients undergo computed tomography (CT), magnetic resonance imaging (MRI), and/or bone scan at baseline.

STEP 2: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive pertuzumab IV over 30-60 minutes on days 1 and 22 of each cycle, trastuzumab IV over 30-90 minutes on days 1 and 22 of each cycle, and paclitaxel IV over 60 minutes on days 1, 8, 15, 22, 29, and 36 of each cycle or docetaxel IV over 60 minutes on days 1 and 22 of each cycle. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive atezolizumab IV over 30-60 minutes on day 22 of cycle 1 and days 1 and 22 of subsequent cycles. Cycles repeat every 6 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT or MRI at baseline, prior to weeks 10, 19, 28 and then at 9, 12, 15, 18, 21, and 24 months from study entry, every 3 months through year 3, every 6 months for years 4 and 5, and then every 6 months for years 6 through 10 from study entry. Patients undergo a bone scan at baseline, every 6 months from study entry, every 6 months through year 3, and every 12 months for years 4 and 5.

ARM II: Patients receive pertuzumab, trastuzumab, and paclitaxel or docetaxel as in Arm I. Patients also receive placebo IV 30-60 minutes on day 22 of cycle 1 and days 1 and 22 of subsequent cycles. Cycles repeat every 6 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT or MRI at baseline, prior to weeks 10, 19, 28 and then at 9, 12, 15, 18, 21, and 24 months from study entry, every 3 months through year 3, every 6 months for years 4 and 5, and then every 6 months for years 6 through 10 from study entry. Patients undergo a bone scan at baseline, every 6 months from study entry, every 6 months through year 3, and every 12 months for years 4 and 5.

After completion of study treatment, patients are followed up at 30 days and every 3 months for 3 years and then every 6 months for 5 years.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
190
Inclusion Criteria

  • The patient must have signed and dated an Institutional Review Board (IRB)-approved consent form that conforms to federal and institutional guidelines

  • The trial is open to female and male patients

  • Patients must be >= 18 years old

  • Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

  • Histologically confirmed adenocarcinoma of the breast with locally recurrent, unresectable disease or metastatic disease outside the central nervous system (CNS) confirmed as described below; eligible patients include those with either:

    • De novo metastatic disease presenting without prior history of HER2-positive breast cancer:

      • Diagnosis should have been made from a biopsy of a metastatic disease site, but biopsy from the breast primary or involved regional lymph nodes is acceptable if biopsy of the metastatic sites was thought to carry excessive risk for the patient

    • Locally recurrent or metastatic disease following prior therapy for early breast cancer:

      • Diagnosis must have been made from the biopsy of the locally recurrent or metastatic disease
      • There must be an interval of >= 6 months between completion of neoadjuvant/adjuvant HER2-targeted therapy and documentation of locally recurrent or metastatic HER2-positive disease by biopsy

  • Patients must have measurable disease based on RECIST 1.1, as determined by the site, which has not been irradiated to be eligible

  • Patients with brain metastases are eligible if they meet ALL the following criteria:

    • Four or fewer metastatic sites to CNS
    • Largest unexcised tumor does not exceed 3 cm
    • No metastases to brain stem, midbrain, pons, medulla or the optic nerves and chiasm
    • Must have measurable disease outside the CNS, based on RECIST 1.1, as determined by the site, which has not been irradiated
    • If patient presented with symptoms from CNS metastases, the symptoms must have resolved with initiation of steroids and initial local therapy (surgery, radiation therapy, or both)
    • Must have been evaluated by Medical Oncologist and plan is to administer trastuzumab, pertuzumab, and a taxane as first-line systemic therapy
    • May have received administration of trastuzumab OR lapatinib concurrently with radiation therapy for brain metastases. Toxicities related to lapatinib if administered, should be =< grade 1 per the CTCAE v5.0, and the lapatinib must have been completed at least 2 weeks prior to study entry
    • No history of intracranial hemorrhage or spinal cord hemorrhage
    • No neurosurgical resection or brain biopsy within 10 days prior to study entry

  • After study entry and before randomization, send tissue for central HER2 confirmation; a tumor specimen obtained at the time of diagnosis of locally recurrent or metastatic disease must have been determined to be HER2-positive based on local testing according to American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines (Wolff 2018); HER2 status should initially be assessed using an Food and Drug Administration (FDA)-cleared IHC assay; positive is defined as IHC 3+ staining intensity; if HER2 IHC results are equivocal (2+), then HER2 status will be determined using a FDA-cleared HER2 in situ hybridization (ISH) test according to ASCO/CAP guidelines; Note: Once HER2-positive is confirmed on central testing, patients will be randomized to atezolizumab/placebo; randomization within 14 days from study entry will ensure that the Pharmaceutical Management Branch (PMB)-supplied agents will be received at the site for treatment on day 22 of cycle 1

  • The tumor specimen obtained at the time of diagnosis used for HER2 testing must also have central testing for PD-L1 status; patients will be eligible irrespective of PD-L1 testing result including PD-L1 indeterminant

  • The tumor specimen obtained at the time of diagnosis used for HER2 and PD-L1 testing should also have central testing for estrogen receptor (ER) and progesterone receptor (PgR) according to current ASCO/CAP guideline recommendations for hormone receptor testing; patients with < 1% ER and PgR staining by IHC will be classified as negative; if enough material for central confirmation of ER and PgR is unavailable, local testing results for ER and PgR may be used for eligibility

  • Localized palliative radiation therapy to sites of non-measurable disease is allowed for symptom management and may begin prior to study entry and continue following study entry while receiving study therapy

  • Patients must have imaging of the chest/abdomen/pelvis, preferably with a CT scan, and a bone scan within 5 weeks prior to study entry; (NOTE: if a patient is unable to receive CT contrast, a MRI of the abdomen/pelvis and non-contrast chest CT should be performed; positron emission tomography/computed tomography [PET/CT] is not an acceptable alternative)

  • MRI of the brain (or contrast CT scan of the brain if patients are unable to undergo MRI) must be obtained in patients with symptoms suggesting possible central nervous system (CNS) metastatic disease; neuroimaging is recommended but not required in asymptomatic patients

  • Absolute neutrophil count (ANC) must be >= 1200/mm^3 (within 14 days prior to study entry)

  • Platelet count must be >= 100,000/mm^3 (within 14 days prior to study entry)

  • Hemoglobin must be >= 8 g/dL (within 14 days prior to study entry)

  • Total bilirubin must be =< 1.5 x upper limit of normal (ULN) for the lab or direct bilirubin =< ULN for patients with bilirubin levels > 1.5 x ULN (within 14 days prior to study entry)

  • Aspartate aminotransferase (AST) and alanine aminotransaminase (ALT) must be =< 2.5 x ULN for the lab or =< 5 x ULN for patients with liver metastases (within 14 days prior to study entry)

  • Serum creatinine =< 1.5 x ULN or measured or calculated creatinine clearance >= 50 mL/min using the Cockcroft-Gault formula for patients with creatinine levels > 1.5 x ULN for the lab (within 14 days prior to study entry)

  • Patients not receiving anti-coagulant therapy must have prothrombin time (PT) and international normalized ratio (INR) =< 1.5 x ULN within 14 days prior to study entry; for laboratories that do not report an ULN for the INR assay, use =< 1.5 as the value for the ULN; patients receiving anti-coagulants should have a baseline INR assessed, but the value does not affect eligibility

  • A serum thyroid-stimulating hormone (TSH) and AM (preferably in morning) cortisol must be obtained within 14 days prior to study entry to obtain a baseline value; patients with abnormal TSH or AM cortisol baseline levels should be further evaluated and managed per institutional standards; asymptomatic patients who require initiation or adjustment of medication or are followed without initiating treatment based on endocrinologist's recommendations are eligible

  • Left ventricular ejection fraction (LVEF) assessment must be performed within 6 weeks prior to study entry; (LVEF assessment performed by echocardiogram is preferred; however, multigated acquisition scan (MUGA) scan may be substituted based on institutional preferences); the LVEF must be >= 50% regardless of the cardiac imaging facility's lower limit of normal

  • Administration of atezolizumab may have an adverse effect on pregnancy and poses a risk to the human fetus, including embryo-lethality; women of child-bearing potential and men must agree to use adequate contraception (non-hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 5 months (150 days) after the last dose of atezolizumab/placebo and 7 months after the last dose of trastuzumab and pertuzumab; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately

  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of study entry are eligible for this trial

Exclusion Criteria

  • Patients with brain metastases are excluded if they meet ANY of the following criteria:

    • Symptoms from brain metastases have not resolved prior to study entry
    • Five or more clearly identified foci of metastases to the brain
    • Largest unexcised tumor exceeds 3 cm
    • Spinal cord metastases
    • Medical Oncologist plans to employ HER2-directed tyrosine kinase inhibitor as component of systemic therapy
    • Metastatic disease limited to CNS

  • Leptomeningeal carcinomatosis

  • History of systemic anti-cancer therapy (e.g., chemotherapy, targeted therapy) for metastatic breast cancer (MBC) except as described in inclusion criteria

  • History of exposure to cumulative doses of doxorubicin greater than 360 mg per square meter of body-surface area or its equivalent

  • Prior treatment with mTOR inhibitors or CDK 4/6 inhibitors in combination with endocrine therapy for treatment of metastatic disease

  • Prior treatment with CD137 agonists or immune checkpoint-blockade therapies, including anti-CD40, anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies

  • History of non-breast malignancies (except for in situ cancers treated only by local excision and basal cell and squamous cell carcinomas of the skin) within 5 years prior to study entry

  • Uncontrolled hypertension defined as sustained systolic blood pressure (BP) > 150 mmHg or diastolic BP > 90 mmHg; (patients with initial BP elevations are eligible if initiation or adjustment of BP medication lowers pressure to meet entry criteria)

  • History of asymptomatic LVEF decline to < 40% during or after prior HER2-targeted therapy even if the current LVEF is >= 50%

  • Cardiac disease (history of and/or active disease) that would preclude the use of the drugs included in the treatment regimens; this includes but is not confined to:

    • Active cardiac disease

      • Angina pectoris that requires the current use of anti-anginal medication;
      • Ventricular arrhythmias except for benign premature ventricular contractions;
      • Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication;
      • Conduction abnormality requiring a pacemaker;
      • Valvular disease with documented compromise in cardiac function; or
      • Symptomatic pericarditis

    • History of cardiac disease

      • Prior myocardial infarction documented by elevated cardiac enzymes or persistent regional wall abnormalities on assessment of left ventricular (LV) function;
      • History of documented congestive heart failure (CHF) defined as symptomatic heart failure with an LVEF < 40%; or
      • Documented cardiomyopathy

  • Nervous system disorder (paresthesia, peripheral motor neuropathy, or peripheral sensory neuropathy) >= grade 2, per the CTCAE v 5.0

  • History of severe allergic, anaphylactic, or other hypersensitivity reactions to pertuzumab or trastuzumab or to any of its excipients, as well as any chimeric or humanized antibodies or fusion proteins

  • Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or other recombinant antibodies

  • Known allergy or hypersensitivity to the components of the atezolizumab formulation or to any of the study drugs or excipients, (e.g., Cremophor EL, polysorbate 80)

  • History or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis

    • Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible

    • Patients with controlled type 1 diabetes mellitus on a stable insulin regimen may be eligible

    • Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:

      • Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations
      • Rash must cover less than 10% of body surface area (BSA)
      • Disease is well controlled at baseline and only requiring low-potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%)
      • No acute exacerbations of underlying conditions within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)

  • Treatment with systemic immunomodulatory medications (including but not limited to interferons, IL-2) within 4 weeks or 5 half-lives of the drug, whichever is longer, prior to study entry

  • Treatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis [anti-TNF] factor agents) within 14 days prior to study entry or anticipation of need for systemic immunosuppressive medications during the study; Note: Intranasal and inhaled corticosteroids or systemic corticosteroids at doses that do not exceed 10 mg/day of prednisone or an equivalent corticosteroid are allowed

  • Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 2 weeks prior to study entry

  • Active hepatitis B virus (HBV) infection, defined as having a positive hepatitis B surface antigen (HBsAg) test at screening; patients with a past or resolved HBV infection, defined as having a negative HBsAg test and a positive total hepatitis B core antibody (HBcAb) test at screening, are eligible for the study if active HBV infection is ruled out on the basis of HBV deoxyribonucleic acid (DNA) viral load per local guidelines

  • Active hepatitis C virus (HCV) infection, defined as having a positive HCV antibody test at screening confirmed by a polymerase chain reaction (PCR) positive for HCV ribonucleic acid (RNA)

  • Patients with clinically active tuberculosis

  • Severe infection within 4 weeks prior to study entry, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia

  • Prior allogeneic stem cell or solid organ transplantation

  • Symptomatic peripheral ischemia

  • History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis or >= grade 1 pulmonary fibrosis, per the CTCAE v5.0, on screening chest CT scan

  • Administration of a live, attenuated vaccine within 4 weeks prior to study entry or anticipation that such vaccine will be required during the study

    • Patients must agree not to receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to study entry, during treatment or within 5 months following the last dose of atezolizumab/placebo

  • Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications

  • Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements or interfere with interpretation of study results

  • Pregnancy or lactation at the time of study entry or intention to become pregnant during the study; (Note: Pregnancy testing according to institutional standards for women of childbearing potential must be performed within 3 days prior to study entry)

  • Use of any investigational product within 4 weeks prior to study entry

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Arm I (pertuzumab, trastuzumab, taxane therapy, atezolizumab)Quality-of-Life AssessmentPatients receive pertuzumab IV over 30-60 minutes on days 1 and 22, trastuzumab IV over 30-90 minutes on days 1 and 22, and paclitaxel IV over 60 minutes on days 1, 8, 15, 22, 29, and 36 or docetaxel IV over 60 minutes on days 1 and 22. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive atezolizumab IV over 30-60 minutes on day 22 of cycle 1 and days 1 and 22 of subsequent cycles. Cycles repeat every 6 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Patients may undergo a biopsy at baseline. Patients undergo a CT or MRI at baseline, prior to weeks 10, 19, 28 and then at 9, 12, 15, 18, 21, and 24 months from study entry, every 3 months through year 3, every 6 months for years 4 and 5, and then every 6 months for years 6 through 10 from study entry. Patients undergo a bone scan at baseline, every 6 months from study entry, every 6 months through year 3, and every 12 months for years 4 and 5.
Arm I (pertuzumab, trastuzumab, taxane therapy, atezolizumab)BiopsyPatients receive pertuzumab IV over 30-60 minutes on days 1 and 22, trastuzumab IV over 30-90 minutes on days 1 and 22, and paclitaxel IV over 60 minutes on days 1, 8, 15, 22, 29, and 36 or docetaxel IV over 60 minutes on days 1 and 22. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive atezolizumab IV over 30-60 minutes on day 22 of cycle 1 and days 1 and 22 of subsequent cycles. Cycles repeat every 6 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Patients may undergo a biopsy at baseline. Patients undergo a CT or MRI at baseline, prior to weeks 10, 19, 28 and then at 9, 12, 15, 18, 21, and 24 months from study entry, every 3 months through year 3, every 6 months for years 4 and 5, and then every 6 months for years 6 through 10 from study entry. Patients undergo a bone scan at baseline, every 6 months from study entry, every 6 months through year 3, and every 12 months for years 4 and 5.
Arm I (pertuzumab, trastuzumab, taxane therapy, atezolizumab)Bone ScanPatients receive pertuzumab IV over 30-60 minutes on days 1 and 22, trastuzumab IV over 30-90 minutes on days 1 and 22, and paclitaxel IV over 60 minutes on days 1, 8, 15, 22, 29, and 36 or docetaxel IV over 60 minutes on days 1 and 22. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive atezolizumab IV over 30-60 minutes on day 22 of cycle 1 and days 1 and 22 of subsequent cycles. Cycles repeat every 6 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Patients may undergo a biopsy at baseline. Patients undergo a CT or MRI at baseline, prior to weeks 10, 19, 28 and then at 9, 12, 15, 18, 21, and 24 months from study entry, every 3 months through year 3, every 6 months for years 4 and 5, and then every 6 months for years 6 through 10 from study entry. Patients undergo a bone scan at baseline, every 6 months from study entry, every 6 months through year 3, and every 12 months for years 4 and 5.
Arm II (pertuzumab, trastuzumab, taxane therapy, placebo)Quality-of-Life AssessmentPatients receive pertuzumab, trastuzumab, and paclitaxel or docetaxel as in Arm I. Patients also receive placebo IV 30-60 minutes on day 1 of cycle 22 and days 1 and 22 of subsequent cycles. Cycles repeat every 6 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Patients may undergo a biopsy at baseline. Patients undergo a CT or MRI at baseline, prior to weeks 10, 19, 28 and then at 9, 12, 15, 18, 21, and 24 months from study entry, every 3 months through year 3, every 6 months for years 4 and 5, and then every 6 months for years 6 through 10 from study entry. Patients undergo a bone scan at baseline every 6 months from study entry, every 6 months through year 3, and every 12 months for years 4 and 5.
Arm I (pertuzumab, trastuzumab, taxane therapy, atezolizumab)Computed TomographyPatients receive pertuzumab IV over 30-60 minutes on days 1 and 22, trastuzumab IV over 30-90 minutes on days 1 and 22, and paclitaxel IV over 60 minutes on days 1, 8, 15, 22, 29, and 36 or docetaxel IV over 60 minutes on days 1 and 22. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive atezolizumab IV over 30-60 minutes on day 22 of cycle 1 and days 1 and 22 of subsequent cycles. Cycles repeat every 6 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Patients may undergo a biopsy at baseline. Patients undergo a CT or MRI at baseline, prior to weeks 10, 19, 28 and then at 9, 12, 15, 18, 21, and 24 months from study entry, every 3 months through year 3, every 6 months for years 4 and 5, and then every 6 months for years 6 through 10 from study entry. Patients undergo a bone scan at baseline, every 6 months from study entry, every 6 months through year 3, and every 12 months for years 4 and 5.
Arm I (pertuzumab, trastuzumab, taxane therapy, atezolizumab)Magnetic Resonance ImagingPatients receive pertuzumab IV over 30-60 minutes on days 1 and 22, trastuzumab IV over 30-90 minutes on days 1 and 22, and paclitaxel IV over 60 minutes on days 1, 8, 15, 22, 29, and 36 or docetaxel IV over 60 minutes on days 1 and 22. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive atezolizumab IV over 30-60 minutes on day 22 of cycle 1 and days 1 and 22 of subsequent cycles. Cycles repeat every 6 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Patients may undergo a biopsy at baseline. Patients undergo a CT or MRI at baseline, prior to weeks 10, 19, 28 and then at 9, 12, 15, 18, 21, and 24 months from study entry, every 3 months through year 3, every 6 months for years 4 and 5, and then every 6 months for years 6 through 10 from study entry. Patients undergo a bone scan at baseline, every 6 months from study entry, every 6 months through year 3, and every 12 months for years 4 and 5.
Arm II (pertuzumab, trastuzumab, taxane therapy, placebo)BiopsyPatients receive pertuzumab, trastuzumab, and paclitaxel or docetaxel as in Arm I. Patients also receive placebo IV 30-60 minutes on day 1 of cycle 22 and days 1 and 22 of subsequent cycles. Cycles repeat every 6 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Patients may undergo a biopsy at baseline. Patients undergo a CT or MRI at baseline, prior to weeks 10, 19, 28 and then at 9, 12, 15, 18, 21, and 24 months from study entry, every 3 months through year 3, every 6 months for years 4 and 5, and then every 6 months for years 6 through 10 from study entry. Patients undergo a bone scan at baseline every 6 months from study entry, every 6 months through year 3, and every 12 months for years 4 and 5.
Arm II (pertuzumab, trastuzumab, taxane therapy, placebo)Bone ScanPatients receive pertuzumab, trastuzumab, and paclitaxel or docetaxel as in Arm I. Patients also receive placebo IV 30-60 minutes on day 1 of cycle 22 and days 1 and 22 of subsequent cycles. Cycles repeat every 6 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Patients may undergo a biopsy at baseline. Patients undergo a CT or MRI at baseline, prior to weeks 10, 19, 28 and then at 9, 12, 15, 18, 21, and 24 months from study entry, every 3 months through year 3, every 6 months for years 4 and 5, and then every 6 months for years 6 through 10 from study entry. Patients undergo a bone scan at baseline every 6 months from study entry, every 6 months through year 3, and every 12 months for years 4 and 5.
Arm II (pertuzumab, trastuzumab, taxane therapy, placebo)Computed TomographyPatients receive pertuzumab, trastuzumab, and paclitaxel or docetaxel as in Arm I. Patients also receive placebo IV 30-60 minutes on day 1 of cycle 22 and days 1 and 22 of subsequent cycles. Cycles repeat every 6 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Patients may undergo a biopsy at baseline. Patients undergo a CT or MRI at baseline, prior to weeks 10, 19, 28 and then at 9, 12, 15, 18, 21, and 24 months from study entry, every 3 months through year 3, every 6 months for years 4 and 5, and then every 6 months for years 6 through 10 from study entry. Patients undergo a bone scan at baseline every 6 months from study entry, every 6 months through year 3, and every 12 months for years 4 and 5.
Arm II (pertuzumab, trastuzumab, taxane therapy, placebo)Magnetic Resonance ImagingPatients receive pertuzumab, trastuzumab, and paclitaxel or docetaxel as in Arm I. Patients also receive placebo IV 30-60 minutes on day 1 of cycle 22 and days 1 and 22 of subsequent cycles. Cycles repeat every 6 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Patients may undergo a biopsy at baseline. Patients undergo a CT or MRI at baseline, prior to weeks 10, 19, 28 and then at 9, 12, 15, 18, 21, and 24 months from study entry, every 3 months through year 3, every 6 months for years 4 and 5, and then every 6 months for years 6 through 10 from study entry. Patients undergo a bone scan at baseline every 6 months from study entry, every 6 months through year 3, and every 12 months for years 4 and 5.
Arm II (pertuzumab, trastuzumab, taxane therapy, placebo)Placebo AdministrationPatients receive pertuzumab, trastuzumab, and paclitaxel or docetaxel as in Arm I. Patients also receive placebo IV 30-60 minutes on day 1 of cycle 22 and days 1 and 22 of subsequent cycles. Cycles repeat every 6 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Patients may undergo a biopsy at baseline. Patients undergo a CT or MRI at baseline, prior to weeks 10, 19, 28 and then at 9, 12, 15, 18, 21, and 24 months from study entry, every 3 months through year 3, every 6 months for years 4 and 5, and then every 6 months for years 6 through 10 from study entry. Patients undergo a bone scan at baseline every 6 months from study entry, every 6 months through year 3, and every 12 months for years 4 and 5.
Arm I (pertuzumab, trastuzumab, taxane therapy, atezolizumab)AtezolizumabPatients receive pertuzumab IV over 30-60 minutes on days 1 and 22, trastuzumab IV over 30-90 minutes on days 1 and 22, and paclitaxel IV over 60 minutes on days 1, 8, 15, 22, 29, and 36 or docetaxel IV over 60 minutes on days 1 and 22. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive atezolizumab IV over 30-60 minutes on day 22 of cycle 1 and days 1 and 22 of subsequent cycles. Cycles repeat every 6 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Patients may undergo a biopsy at baseline. Patients undergo a CT or MRI at baseline, prior to weeks 10, 19, 28 and then at 9, 12, 15, 18, 21, and 24 months from study entry, every 3 months through year 3, every 6 months for years 4 and 5, and then every 6 months for years 6 through 10 from study entry. Patients undergo a bone scan at baseline, every 6 months from study entry, every 6 months through year 3, and every 12 months for years 4 and 5.
Arm I (pertuzumab, trastuzumab, taxane therapy, atezolizumab)DocetaxelPatients receive pertuzumab IV over 30-60 minutes on days 1 and 22, trastuzumab IV over 30-90 minutes on days 1 and 22, and paclitaxel IV over 60 minutes on days 1, 8, 15, 22, 29, and 36 or docetaxel IV over 60 minutes on days 1 and 22. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive atezolizumab IV over 30-60 minutes on day 22 of cycle 1 and days 1 and 22 of subsequent cycles. Cycles repeat every 6 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Patients may undergo a biopsy at baseline. Patients undergo a CT or MRI at baseline, prior to weeks 10, 19, 28 and then at 9, 12, 15, 18, 21, and 24 months from study entry, every 3 months through year 3, every 6 months for years 4 and 5, and then every 6 months for years 6 through 10 from study entry. Patients undergo a bone scan at baseline, every 6 months from study entry, every 6 months through year 3, and every 12 months for years 4 and 5.
Arm I (pertuzumab, trastuzumab, taxane therapy, atezolizumab)PaclitaxelPatients receive pertuzumab IV over 30-60 minutes on days 1 and 22, trastuzumab IV over 30-90 minutes on days 1 and 22, and paclitaxel IV over 60 minutes on days 1, 8, 15, 22, 29, and 36 or docetaxel IV over 60 minutes on days 1 and 22. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive atezolizumab IV over 30-60 minutes on day 22 of cycle 1 and days 1 and 22 of subsequent cycles. Cycles repeat every 6 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Patients may undergo a biopsy at baseline. Patients undergo a CT or MRI at baseline, prior to weeks 10, 19, 28 and then at 9, 12, 15, 18, 21, and 24 months from study entry, every 3 months through year 3, every 6 months for years 4 and 5, and then every 6 months for years 6 through 10 from study entry. Patients undergo a bone scan at baseline, every 6 months from study entry, every 6 months through year 3, and every 12 months for years 4 and 5.
Arm I (pertuzumab, trastuzumab, taxane therapy, atezolizumab)PertuzumabPatients receive pertuzumab IV over 30-60 minutes on days 1 and 22, trastuzumab IV over 30-90 minutes on days 1 and 22, and paclitaxel IV over 60 minutes on days 1, 8, 15, 22, 29, and 36 or docetaxel IV over 60 minutes on days 1 and 22. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive atezolizumab IV over 30-60 minutes on day 22 of cycle 1 and days 1 and 22 of subsequent cycles. Cycles repeat every 6 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Patients may undergo a biopsy at baseline. Patients undergo a CT or MRI at baseline, prior to weeks 10, 19, 28 and then at 9, 12, 15, 18, 21, and 24 months from study entry, every 3 months through year 3, every 6 months for years 4 and 5, and then every 6 months for years 6 through 10 from study entry. Patients undergo a bone scan at baseline, every 6 months from study entry, every 6 months through year 3, and every 12 months for years 4 and 5.
Arm I (pertuzumab, trastuzumab, taxane therapy, atezolizumab)TrastuzumabPatients receive pertuzumab IV over 30-60 minutes on days 1 and 22, trastuzumab IV over 30-90 minutes on days 1 and 22, and paclitaxel IV over 60 minutes on days 1, 8, 15, 22, 29, and 36 or docetaxel IV over 60 minutes on days 1 and 22. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive atezolizumab IV over 30-60 minutes on day 22 of cycle 1 and days 1 and 22 of subsequent cycles. Cycles repeat every 6 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Patients may undergo a biopsy at baseline. Patients undergo a CT or MRI at baseline, prior to weeks 10, 19, 28 and then at 9, 12, 15, 18, 21, and 24 months from study entry, every 3 months through year 3, every 6 months for years 4 and 5, and then every 6 months for years 6 through 10 from study entry. Patients undergo a bone scan at baseline, every 6 months from study entry, every 6 months through year 3, and every 12 months for years 4 and 5.
Arm II (pertuzumab, trastuzumab, taxane therapy, placebo)DocetaxelPatients receive pertuzumab, trastuzumab, and paclitaxel or docetaxel as in Arm I. Patients also receive placebo IV 30-60 minutes on day 1 of cycle 22 and days 1 and 22 of subsequent cycles. Cycles repeat every 6 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Patients may undergo a biopsy at baseline. Patients undergo a CT or MRI at baseline, prior to weeks 10, 19, 28 and then at 9, 12, 15, 18, 21, and 24 months from study entry, every 3 months through year 3, every 6 months for years 4 and 5, and then every 6 months for years 6 through 10 from study entry. Patients undergo a bone scan at baseline every 6 months from study entry, every 6 months through year 3, and every 12 months for years 4 and 5.
Arm II (pertuzumab, trastuzumab, taxane therapy, placebo)PaclitaxelPatients receive pertuzumab, trastuzumab, and paclitaxel or docetaxel as in Arm I. Patients also receive placebo IV 30-60 minutes on day 1 of cycle 22 and days 1 and 22 of subsequent cycles. Cycles repeat every 6 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Patients may undergo a biopsy at baseline. Patients undergo a CT or MRI at baseline, prior to weeks 10, 19, 28 and then at 9, 12, 15, 18, 21, and 24 months from study entry, every 3 months through year 3, every 6 months for years 4 and 5, and then every 6 months for years 6 through 10 from study entry. Patients undergo a bone scan at baseline every 6 months from study entry, every 6 months through year 3, and every 12 months for years 4 and 5.
Arm II (pertuzumab, trastuzumab, taxane therapy, placebo)PertuzumabPatients receive pertuzumab, trastuzumab, and paclitaxel or docetaxel as in Arm I. Patients also receive placebo IV 30-60 minutes on day 1 of cycle 22 and days 1 and 22 of subsequent cycles. Cycles repeat every 6 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Patients may undergo a biopsy at baseline. Patients undergo a CT or MRI at baseline, prior to weeks 10, 19, 28 and then at 9, 12, 15, 18, 21, and 24 months from study entry, every 3 months through year 3, every 6 months for years 4 and 5, and then every 6 months for years 6 through 10 from study entry. Patients undergo a bone scan at baseline every 6 months from study entry, every 6 months through year 3, and every 12 months for years 4 and 5.
Arm II (pertuzumab, trastuzumab, taxane therapy, placebo)TrastuzumabPatients receive pertuzumab, trastuzumab, and paclitaxel or docetaxel as in Arm I. Patients also receive placebo IV 30-60 minutes on day 1 of cycle 22 and days 1 and 22 of subsequent cycles. Cycles repeat every 6 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Patients may undergo a biopsy at baseline. Patients undergo a CT or MRI at baseline, prior to weeks 10, 19, 28 and then at 9, 12, 15, 18, 21, and 24 months from study entry, every 3 months through year 3, every 6 months for years 4 and 5, and then every 6 months for years 6 through 10 from study entry. Patients undergo a bone scan at baseline every 6 months from study entry, every 6 months through year 3, and every 12 months for years 4 and 5.
Primary Outcome Measures
NameTimeMethod
Progression free survivalThe time from randomization to the first documented progressive disease every 6 months, assessed up to 8 years

Will be determined using the current Response Evaluation Criteria in Solid Tumors 1.1 criteria. Analysis will be based on the intent to treat population. The stratified log-rank test will be used to compare the progression free survival between the two treatment arms with the following stratification factors: prior neoadjuvant or adjuvant therapy with trastuzumab (no; yes), estrogen receptor status (positive; negative), disease sites (any visceral without brain metastasis; non-visceral only without brain metastasis; brain metastasis), and choice of taxane (paclitaxel; docetaxel). The Kaplan-Meier estimates will be calculated by treatment arms. Stratified Cox proportional hazards models to estimate the hazard ratio.

Secondary Outcome Measures
NameTimeMethod
Frequency of adverse events, including late immune-related toxicitiesEvery 6 months up to 8 years

Will be categorized using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0. Comparisons of the adverse events between the two treatment arms will be done by the Fisher's exact test.

Overall survivalThe time from randomization to death from any cause every 6 months, assessed up to 8 years

Analysis will be based on the intent to treat population. The stratification factors are the same as what are used in the stratified log-rank test for the primary analysis on progression free survival. The Kaplan-Meier estimates will be calculated by treatment arms. Stratified Cox proportional hazards models to estimate the hazard ratio.

Overall objective responseEvery 6 months up to 8 years

Defined as complete response or partial response. Will be determined using Response Evaluation Criteria in Solid Tumors 1.1 criteria. The stratified Cochran-Mantel-Haenszel test will be used to compare the object response between the treatment arms.

Trial Locations

Locations (672)

Good Samaritan Hospital - Cancer Centers of Colorado

🇺🇸

Lafayette, Colorado, United States

Banner MD Anderson Cancer Center

🇺🇸

Gilbert, Arizona, United States

Intermountain Health Lutheran Hospital

🇺🇸

Wheat Ridge, Colorado, United States

University of Alabama at Birmingham Cancer Center

🇺🇸

Birmingham, Alabama, United States

CTCA at Western Regional Medical Center

🇺🇸

Goodyear, Arizona, United States

Katmai Oncology Group

🇺🇸

Anchorage, Alaska, United States

Banner-University Medical Center Phoenix

🇺🇸

Phoenix, Arizona, United States

Banner Boswell Medical Center

🇺🇸

Sun City, Arizona, United States

NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro

🇺🇸

Jonesboro, Arkansas, United States

Kaiser Permanente-Anaheim

🇺🇸

Anaheim, California, United States

Kaiser Permanente-Deer Valley Medical Center

🇺🇸

Antioch, California, United States

Kaiser Permanente-Baldwin Park

🇺🇸

Baldwin Park, California, United States

Kaiser Permanente-Bellflower

🇺🇸

Bellflower, California, United States

Alta Bates Summit Medical Center-Herrick Campus

🇺🇸

Berkeley, California, United States

UC Irvine Health Cancer Center-Newport

🇺🇸

Costa Mesa, California, United States

City of Hope Comprehensive Cancer Center

🇺🇸

Duarte, California, United States

Kaiser Permanente Dublin

🇺🇸

Dublin, California, United States

Kaiser Permanente-Fontana

🇺🇸

Fontana, California, United States

Kaiser Permanente-Fremont

🇺🇸

Fremont, California, United States

Palo Alto Medical Foundation-Fremont

🇺🇸

Fremont, California, United States

Washington Hospital

🇺🇸

Fremont, California, United States

Kaiser Permanente-Fresno

🇺🇸

Fresno, California, United States

Kaiser Permanente - Harbor City

🇺🇸

Harbor City, California, United States

Loma Linda University Medical Center

🇺🇸

Loma Linda, California, United States

Kaiser Permanente Los Angeles Medical Center

🇺🇸

Los Angeles, California, United States

Kaiser Permanente West Los Angeles

🇺🇸

Los Angeles, California, United States

Palo Alto Medical Foundation-Santa Cruz

🇺🇸

Santa Cruz, California, United States

Memorial Medical Center

🇺🇸

Modesto, California, United States

Kaiser Permanente-Irvine

🇺🇸

Irvine, California, United States

Kaiser Permanente-Modesto

🇺🇸

Modesto, California, United States

Palo Alto Medical Foundation-Camino Division

🇺🇸

Mountain View, California, United States

Kaiser Permanente-Oakland

🇺🇸

Oakland, California, United States

Kaiser Permanente-Ontario

🇺🇸

Ontario, California, United States

Saint Joseph Hospital - Orange

🇺🇸

Orange, California, United States

UC Irvine Health/Chao Family Comprehensive Cancer Center

🇺🇸

Orange, California, United States

Desert Regional Medical Center

🇺🇸

Palm Springs, California, United States

Palo Alto Medical Foundation Health Care

🇺🇸

Palo Alto, California, United States

Stanford Cancer Institute Palo Alto

🇺🇸

Palo Alto, California, United States

Kaiser Permanente - Panorama City

🇺🇸

Panorama City, California, United States

Kaiser Permanente-Richmond

🇺🇸

Richmond, California, United States

Kaiser Permanente-Riverside

🇺🇸

Riverside, California, United States

Kaiser Permanente-Roseville

🇺🇸

Roseville, California, United States

Kaiser Permanente Downtown Commons

🇺🇸

Sacramento, California, United States

Sutter Medical Center Sacramento

🇺🇸

Sacramento, California, United States

Kaiser Permanente-South Sacramento

🇺🇸

Sacramento, California, United States

Kaiser Permanente-San Diego Zion

🇺🇸

San Diego, California, United States

California Pacific Medical Center-Pacific Campus

🇺🇸

San Francisco, California, United States

Kaiser Permanente-San Francisco

🇺🇸

San Francisco, California, United States

Kaiser Permanente-Santa Teresa-San Jose

🇺🇸

San Jose, California, United States

Kaiser Permanente San Leandro

🇺🇸

San Leandro, California, United States

Kaiser Permanente-San Marcos

🇺🇸

San Marcos, California, United States

Kaiser San Rafael-Gallinas

🇺🇸

San Rafael, California, United States

Kaiser Permanente Medical Center - Santa Clara

🇺🇸

Santa Clara, California, United States

Kaiser Permanente-Santa Rosa

🇺🇸

Santa Rosa, California, United States

City of Hope South Pasadena

🇺🇸

South Pasadena, California, United States

Kaiser Permanente-South San Francisco

🇺🇸

South San Francisco, California, United States

Kaiser Permanente-Stockton

🇺🇸

Stockton, California, United States

Palo Alto Medical Foundation-Sunnyvale

🇺🇸

Sunnyvale, California, United States

City of Hope South Bay

🇺🇸

Torrance, California, United States

Gene Upshaw Memorial Tahoe Forest Cancer Center

🇺🇸

Truckee, California, United States

City of Hope Upland

🇺🇸

Upland, California, United States

Kaiser Permanente Medical Center-Vacaville

🇺🇸

Vacaville, California, United States

Kaiser Permanente-Vallejo

🇺🇸

Vallejo, California, United States

Sutter Solano Medical Center/Cancer Center

🇺🇸

Vallejo, California, United States

Kaiser Permanente-Walnut Creek

🇺🇸

Walnut Creek, California, United States

Kaiser Permanente-Woodland Hills

🇺🇸

Woodland Hills, California, United States

Rocky Mountain Cancer Centers-Aurora

🇺🇸

Aurora, Colorado, United States

UCHealth University of Colorado Hospital

🇺🇸

Aurora, Colorado, United States

Rocky Mountain Cancer Centers-Boulder

🇺🇸

Boulder, Colorado, United States

UCHealth Memorial Hospital Central

🇺🇸

Colorado Springs, Colorado, United States

Memorial Hospital North

🇺🇸

Colorado Springs, Colorado, United States

Cancer Center of Colorado at Sloan's Lake

🇺🇸

Denver, Colorado, United States

SCL Health Saint Joseph Hospital

🇺🇸

Denver, Colorado, United States

Poudre Valley Hospital

🇺🇸

Fort Collins, Colorado, United States

Cancer Care and Hematology-Fort Collins

🇺🇸

Fort Collins, Colorado, United States

UCHealth Highlands Ranch Hospital

🇺🇸

Highlands Ranch, Colorado, United States

UCHealth Greeley Hospital

🇺🇸

Greeley, Colorado, United States

Rocky Mountain Cancer Centers-Littleton

🇺🇸

Littleton, Colorado, United States

Rocky Mountain Cancer Centers-Sky Ridge

🇺🇸

Lone Tree, Colorado, United States

Medical Center of the Rockies

🇺🇸

Loveland, Colorado, United States

Smilow Cancer Hospital-Derby Care Center

🇺🇸

Derby, Connecticut, United States

Danbury Hospital

🇺🇸

Danbury, Connecticut, United States

Smilow Cancer Hospital Care Center-Fairfield

🇺🇸

Fairfield, Connecticut, United States

Smilow Cancer Hospital Care Center at Greenwich

🇺🇸

Greenwich, Connecticut, United States

Smilow Cancer Hospital Care Center - Guilford

🇺🇸

Guilford, Connecticut, United States

Hartford Hospital

🇺🇸

Hartford, Connecticut, United States

Smilow Cancer Hospital Care Center at Saint Francis

🇺🇸

Hartford, Connecticut, United States

Yale University

🇺🇸

New Haven, Connecticut, United States

Yale-New Haven Hospital North Haven Medical Center

🇺🇸

North Haven, Connecticut, United States

Norwalk Hospital

🇺🇸

Norwalk, Connecticut, United States

Smilow Cancer Hospital-Orange Care Center

🇺🇸

Orange, Connecticut, United States

Smilow Cancer Hospital-Torrington Care Center

🇺🇸

Torrington, Connecticut, United States

Smilow Cancer Hospital Care Center-Trumbull

🇺🇸

Trumbull, Connecticut, United States

Smilow Cancer Hospital-Waterbury Care Center

🇺🇸

Waterbury, Connecticut, United States

Smilow Cancer Hospital Care Center - Waterford

🇺🇸

Waterford, Connecticut, United States

Beebe South Coastal Health Campus

🇺🇸

Millville, Delaware, United States

Helen F Graham Cancer Center

🇺🇸

Newark, Delaware, United States

Medical Oncology Hematology Consultants PA

🇺🇸

Newark, Delaware, United States

Beebe Health Campus

🇺🇸

Rehoboth Beach, Delaware, United States

Kaiser Permanente-Capitol Hill Medical Center

🇺🇸

Washington, District of Columbia, United States

AdventHealth Altamonte

🇺🇸

Altamonte Springs, Florida, United States

GenesisCare USA - Aventura FP

🇺🇸

Aventura, Florida, United States

GenesisCare USA - Boca Ration FP06

🇺🇸

Boca Raton, Florida, United States

AdventHealth Celebration

🇺🇸

Celebration, Florida, United States

UM Sylvester Comprehensive Cancer Center at Coral Gables

🇺🇸

Coral Gables, Florida, United States

University of Miami Miller School of Medicine-Sylvester Cancer Center

🇺🇸

Miami, Florida, United States

UM Sylvester Comprehensive Cancer Center at Deerfield Beach

🇺🇸

Deerfield Beach, Florida, United States

Holy Cross Hospital

🇺🇸

Fort Lauderdale, Florida, United States

Broward Health Medical Center

🇺🇸

Fort Lauderdale, Florida, United States

Mount Sinai Medical Center

🇺🇸

Miami Beach, Florida, United States

UM Sylvester Comprehensive Cancer Center at Kendall

🇺🇸

Miami, Florida, United States

AdventHealth Orlando

🇺🇸

Orlando, Florida, United States

Orlando Health Cancer Institute

🇺🇸

Orlando, Florida, United States

Sacred Heart Hospital

🇺🇸

Pensacola, Florida, United States

UM Sylvester Comprehensive Cancer Center at Plantation

🇺🇸

Plantation, Florida, United States

University Cancer and Blood Center LLC

🇺🇸

Athens, Georgia, United States

Piedmont Hospital

🇺🇸

Atlanta, Georgia, United States

Northside Hospital

🇺🇸

Atlanta, Georgia, United States

Augusta Oncology Associates PC-D'Antignac

🇺🇸

Augusta, Georgia, United States

Cleveland Clinic-Weston

🇺🇸

Weston, Florida, United States

Phoebe Putney Memorial Hospital

🇺🇸

Albany, Georgia, United States

Augusta Oncology Associates PC-Wheeler

🇺🇸

Augusta, Georgia, United States

Northside Hospital - Duluth

🇺🇸

Duluth, Georgia, United States

Piedmont Fayette Hospital

🇺🇸

Fayetteville, Georgia, United States

Eisenhower Army Medical Center

🇺🇸

Fort Eisenhower, Georgia, United States

Northside Hospital - Gwinnett

🇺🇸

Lawrenceville, Georgia, United States

Piedmont Newnan Hospital

🇺🇸

Newnan, Georgia, United States

Lewis Cancer and Research Pavilion at Saint Joseph's/Candler

🇺🇸

Savannah, Georgia, United States

Suburban Hematology Oncology Associates - Snellville

🇺🇸

Snellville, Georgia, United States

Piedmont Henry Hospital

🇺🇸

Stockbridge, Georgia, United States

Hawaii Cancer Care - Westridge

🇺🇸

'Aiea, Hawaii, United States

Queen's Medical Center

🇺🇸

Honolulu, Hawaii, United States

Pali Momi Medical Center

🇺🇸

'Aiea, Hawaii, United States

Hawaii Cancer Care Inc - Waterfront Plaza

🇺🇸

Honolulu, Hawaii, United States

Straub Clinic and Hospital

🇺🇸

Honolulu, Hawaii, United States

Queen's Cancer Cenrer - POB I

🇺🇸

Honolulu, Hawaii, United States

Queen's Cancer Center - Kuakini

🇺🇸

Honolulu, Hawaii, United States

Kaiser Permanente Moanalua Medical Center

🇺🇸

Honolulu, Hawaii, United States

Kapiolani Medical Center for Women and Children

🇺🇸

Honolulu, Hawaii, United States

Saint Alphonsus Cancer Care Center-Boise

🇺🇸

Boise, Idaho, United States

Saint Luke's Cancer Institute - Boise

🇺🇸

Boise, Idaho, United States

Saint Alphonsus Cancer Care Center-Caldwell

🇺🇸

Caldwell, Idaho, United States

Kootenai Health - Coeur d'Alene

🇺🇸

Coeur d'Alene, Idaho, United States

Saint Luke's Cancer Institute - Fruitland

🇺🇸

Fruitland, Idaho, United States

Saint Luke's Cancer Institute - Meridian

🇺🇸

Meridian, Idaho, United States

Saint Luke's Cancer Institute - Nampa

🇺🇸

Nampa, Idaho, United States

Saint Alphonsus Cancer Care Center-Nampa

🇺🇸

Nampa, Idaho, United States

Kootenai Clinic Cancer Services - Post Falls

🇺🇸

Post Falls, Idaho, United States

Kootenai Clinic Cancer Services - Sandpoint

🇺🇸

Sandpoint, Idaho, United States

Saint Luke's Cancer Institute - Twin Falls

🇺🇸

Twin Falls, Idaho, United States

Rush - Copley Medical Center

🇺🇸

Aurora, Illinois, United States

Illinois CancerCare-Bloomington

🇺🇸

Bloomington, Illinois, United States

Illinois CancerCare-Canton

🇺🇸

Canton, Illinois, United States

Illinois CancerCare-Carthage

🇺🇸

Carthage, Illinois, United States

Northwestern University

🇺🇸

Chicago, Illinois, United States

Rush University Medical Center

🇺🇸

Chicago, Illinois, United States

University of Illinois

🇺🇸

Chicago, Illinois, United States

Advocate Illinois Masonic Medical Center

🇺🇸

Chicago, Illinois, United States

AMG Crystal Lake - Oncology

🇺🇸

Crystal Lake, Illinois, United States

Carle at The Riverfront

🇺🇸

Danville, Illinois, United States

Cancer Care Specialists of Illinois - Decatur

🇺🇸

Decatur, Illinois, United States

Advocate Good Samaritan Hospital

🇺🇸

Downers Grove, Illinois, United States

Carle Physician Group-Effingham

🇺🇸

Effingham, Illinois, United States

Crossroads Cancer Center

🇺🇸

Effingham, Illinois, United States

Elmhurst Memorial Hospital

🇺🇸

Elmhurst, Illinois, United States

Illinois CancerCare-Eureka

🇺🇸

Eureka, Illinois, United States

NorthShore University HealthSystem-Evanston Hospital

🇺🇸

Evanston, Illinois, United States

Illinois CancerCare-Galesburg

🇺🇸

Galesburg, Illinois, United States

Ingalls Memorial Hospital

🇺🇸

Harvey, Illinois, United States

NorthShore University HealthSystem-Glenbrook Hospital

🇺🇸

Glenview, Illinois, United States

Advocate South Suburban Hospital

🇺🇸

Hazel Crest, Illinois, United States

NorthShore University HealthSystem-Highland Park Hospital

🇺🇸

Highland Park, Illinois, United States

Duly Health and Care Joliet

🇺🇸

Joliet, Illinois, United States

Illinois CancerCare-Kewanee Clinic

🇺🇸

Kewanee, Illinois, United States

Northwestern Medicine Lake Forest Hospital

🇺🇸

Lake Forest, Illinois, United States

AMG Libertyville - Oncology

🇺🇸

Libertyville, Illinois, United States

Condell Memorial Hospital

🇺🇸

Libertyville, Illinois, United States

Illinois CancerCare-Macomb

🇺🇸

Macomb, Illinois, United States

Carle Physician Group-Mattoon/Charleston

🇺🇸

Mattoon, Illinois, United States

Edward Hospital/Cancer Center

🇺🇸

Naperville, Illinois, United States

Advocate Lutheran General Hospital

🇺🇸

Park Ridge, Illinois, United States

Cancer Care Center of O'Fallon

🇺🇸

O'Fallon, Illinois, United States

Advocate Christ Medical Center

🇺🇸

Oak Lawn, Illinois, United States

Illinois CancerCare-Ottawa Clinic

🇺🇸

Ottawa, Illinois, United States

Illinois CancerCare-Pekin

🇺🇸

Pekin, Illinois, United States

Illinois CancerCare-Peoria

🇺🇸

Peoria, Illinois, United States

Illinois CancerCare-Peru

🇺🇸

Peru, Illinois, United States

Edward Hospital/Cancer Center?Plainfield

🇺🇸

Plainfield, Illinois, United States

Illinois CancerCare-Princeton

🇺🇸

Princeton, Illinois, United States

UW Health Carbone Cancer Center Rockford

🇺🇸

Rockford, Illinois, United States

Springfield Clinic

🇺🇸

Springfield, Illinois, United States

Southern Illinois University School of Medicine

🇺🇸

Springfield, Illinois, United States

Carle Cancer Center

🇺🇸

Urbana, Illinois, United States

Midwestern Regional Medical Center

🇺🇸

Zion, Illinois, United States

Illinois CancerCare - Washington

🇺🇸

Washington, Illinois, United States

Northwest Cancer Center - Main Campus

🇺🇸

Crown Point, Indiana, United States

Northwest Oncology LLC

🇺🇸

Dyer, Indiana, United States

Northwest Cancer Center - Hobart

🇺🇸

Hobart, Indiana, United States

Saint Mary Medical Center

🇺🇸

Hobart, Indiana, United States

Saint Catherine Hospital

🇺🇸

Indianapolis, Indiana, United States

The Community Hospital

🇺🇸

Munster, Indiana, United States

Northwest Cancer Center - Valparaiso

🇺🇸

Valparaiso, Indiana, United States

Women's Diagnostic Center - Munster

🇺🇸

Munster, Indiana, United States

Memorial Hospital of South Bend

🇺🇸

South Bend, Indiana, United States

Mary Greeley Medical Center

🇺🇸

Ames, Iowa, United States

McFarland Clinic - Ames

🇺🇸

Ames, Iowa, United States

University of Iowa Healthcare Cancer Services Quad Cities

🇺🇸

Bettendorf, Iowa, United States

Mercy Hospital

🇺🇸

Coon Rapids, Minnesota, United States

McFarland Clinic - Boone

🇺🇸

Boone, Iowa, United States

Saint Anthony Regional Hospital

🇺🇸

Carroll, Iowa, United States

Oncology Associates at Mercy Medical Center

🇺🇸

Cedar Rapids, Iowa, United States

Mercy Cancer Center-West Lakes

🇺🇸

Clive, Iowa, United States

Mission Cancer and Blood - West Des Moines

🇺🇸

Clive, Iowa, United States

Iowa Methodist Medical Center

🇺🇸

Des Moines, Iowa, United States

Mission Cancer and Blood - Des Moines

🇺🇸

Des Moines, Iowa, United States

Broadlawns Medical Center

🇺🇸

Des Moines, Iowa, United States

Mercy Medical Center - Des Moines

🇺🇸

Des Moines, Iowa, United States

Mission Cancer and Blood - Laurel

🇺🇸

Des Moines, Iowa, United States

Trinity Regional Medical Center

🇺🇸

Fort Dodge, Iowa, United States

University of Iowa/Holden Comprehensive Cancer Center

🇺🇸

Iowa City, Iowa, United States

Iowa Lutheran Hospital

🇺🇸

Des Moines, Iowa, United States

McFarland Clinic - Trinity Cancer Center

🇺🇸

Fort Dodge, Iowa, United States

McFarland Clinic - Jefferson

🇺🇸

Jefferson, Iowa, United States

McFarland Clinic - Marshalltown

🇺🇸

Marshalltown, Iowa, United States

HaysMed

🇺🇸

Hays, Kansas, United States

University of Kansas Cancer Center-West

🇺🇸

Kansas City, Kansas, United States

Olathe Health Cancer Center

🇺🇸

Olathe, Kansas, United States

University of Kansas Cancer Center-Overland Park

🇺🇸

Overland Park, Kansas, United States

University of Kansas Hospital-Westwood Cancer Center

🇺🇸

Westwood, Kansas, United States

Saint Elizabeth Healthcare Edgewood

🇺🇸

Edgewood, Kentucky, United States

Baptist Health Lexington

🇺🇸

Lexington, Kentucky, United States

Saint Joseph Hospital East

🇺🇸

Lexington, Kentucky, United States

University of Kentucky/Markey Cancer Center

🇺🇸

Lexington, Kentucky, United States

Baptist Health Louisville

🇺🇸

Louisville, Kentucky, United States

LSU Health Baton Rouge-North Clinic

🇺🇸

Baton Rouge, Louisiana, United States

Our Lady of the Lake Physician Group

🇺🇸

Baton Rouge, Louisiana, United States

Louisiana Hematology Oncology Associates LLC

🇺🇸

Baton Rouge, Louisiana, United States

Mary Bird Perkins Cancer Center

🇺🇸

Baton Rouge, Louisiana, United States

Our Lady of the Lake Medical Oncology

🇺🇸

Baton Rouge, Louisiana, United States

Woman's Hospital

🇺🇸

Baton Rouge, Louisiana, United States

Northshore Oncology Associates-Covington

🇺🇸

Covington, Louisiana, United States

Oncology Center of The South Incorporated

🇺🇸

Houma, Louisiana, United States

Harold Alfond Center for Cancer Care

🇺🇸

Augusta, Maine, United States

Waldo County General Hospital

🇺🇸

Belfast, Maine, United States

MaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford

🇺🇸

Biddeford, Maine, United States

Lafayette Family Cancer Center-EMMC

🇺🇸

Brewer, Maine, United States

Maine Medical Partners - South Portland

🇺🇸

South Portland, Maine, United States

University of Maryland/Greenebaum Cancer Center

🇺🇸

Baltimore, Maryland, United States

Penobscot Bay Medical Center

🇺🇸

Rockport, Maine, United States

MaineHealth/SMHC Cancer Care and Blood Disorders-Sanford

🇺🇸

Sanford, Maine, United States

Greater Baltimore Medical Center

🇺🇸

Baltimore, Maryland, United States

Saint Agnes Hospital

🇺🇸

Baltimore, Maryland, United States

Kaiser Permanente-Woodlawn Medical Center

🇺🇸

Baltimore, Maryland, United States

UM Upper Chesapeake Medical Center

🇺🇸

Bel Air, Maryland, United States

University of Maryland Shore Medical Center at Easton

🇺🇸

Easton, Maryland, United States

FMH James M Stockman Cancer Institute

🇺🇸

Frederick, Maryland, United States

Kaiser Permanente-Gaithersburg Medical Center

🇺🇸

Gaithersburg, Maryland, United States

Kaiser Permanente - Kensington Medical Center

🇺🇸

Kensington, Maryland, United States

Beverly Hospital

🇺🇸

Beverly, Massachusetts, United States

Kaiser Permanente - Largo Medical Center

🇺🇸

Largo, Maryland, United States

UM Saint Joseph Medical Center

🇺🇸

Towson, Maryland, United States

Lahey Hospital and Medical Center

🇺🇸

Burlington, Massachusetts, United States

Addison Gilbert Hospital

🇺🇸

Gloucester, Massachusetts, United States

UMass Memorial Medical Center - University Campus

🇺🇸

Worcester, Massachusetts, United States

Trinity Health Saint Joseph Mercy Hospital Ann Arbor

🇺🇸

Ann Arbor, Michigan, United States

Trinity Health IHA Medical Group Hematology Oncology - Brighton

🇺🇸

Brighton, Michigan, United States

University of Michigan Comprehensive Cancer Center

🇺🇸

Ann Arbor, Michigan, United States

Trinity Health Medical Center - Brighton

🇺🇸

Brighton, Michigan, United States

McLaren Cancer Institute-Bay City

🇺🇸

Bay City, Michigan, United States

Trinity Health IHA Medical Group Hematology Oncology - Canton

🇺🇸

Canton, Michigan, United States

Trinity Health Medical Center - Canton

🇺🇸

Canton, Michigan, United States

Caro Cancer Center

🇺🇸

Caro, Michigan, United States

Chelsea Hospital

🇺🇸

Chelsea, Michigan, United States

McLaren Cancer Institute-Clarkston

🇺🇸

Clarkston, Michigan, United States

Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital

🇺🇸

Chelsea, Michigan, United States

Hematology Oncology Consultants-Clarkston

🇺🇸

Clarkston, Michigan, United States

Newland Medical Associates-Clarkston

🇺🇸

Clarkston, Michigan, United States

Henry Ford Macomb Hospital-Clinton Township

🇺🇸

Clinton Township, Michigan, United States

Henry Ford Hospital

🇺🇸

Detroit, Michigan, United States

Wayne State University/Karmanos Cancer Institute

🇺🇸

Detroit, Michigan, United States

Ascension Saint John Hospital

🇺🇸

Detroit, Michigan, United States

Great Lakes Cancer Management Specialists-Doctors Park

🇺🇸

East China Township, Michigan, United States

Weisberg Cancer Treatment Center

🇺🇸

Farmington Hills, Michigan, United States

Corewell Health Farmington Hills Hospital

🇺🇸

Farmington Hills, Michigan, United States

Genesee Hematology Oncology PC

🇺🇸

Flint, Michigan, United States

Genesee Cancer and Blood Disease Treatment Center

🇺🇸

Flint, Michigan, United States

Genesys Hurley Cancer Institute

🇺🇸

Flint, Michigan, United States

McLaren Cancer Institute-Flint

🇺🇸

Flint, Michigan, United States

Singh and Arora Hematology Oncology PC

🇺🇸

Flint, Michigan, United States

Academic Hematology Oncology Specialists

🇺🇸

Grosse Pointe Woods, Michigan, United States

Corewell Health Grand Rapids Hospitals - Butterworth Hospital

🇺🇸

Grand Rapids, Michigan, United States

Great Lakes Cancer Management Specialists-Van Elslander Cancer Center

🇺🇸

Grosse Pointe Woods, Michigan, United States

Allegiance Health

🇺🇸

Jackson, Michigan, United States

Michigan Breast Specialists-Grosse Pointe Woods

🇺🇸

Grosse Pointe Woods, Michigan, United States

West Michigan Cancer Center

🇺🇸

Kalamazoo, Michigan, United States

Karmanos Cancer Institute at McLaren Greater Lansing

🇺🇸

Lansing, Michigan, United States

University of Michigan Health - Sparrow Lansing

🇺🇸

Lansing, Michigan, United States

Mid-Michigan Physicians-Lansing

🇺🇸

Lansing, Michigan, United States

McLaren Cancer Institute-Lapeer Region

🇺🇸

Lapeer, Michigan, United States

Hope Cancer Clinic

🇺🇸

Livonia, Michigan, United States

Saint Mary's Oncology/Hematology Associates of Marlette

🇺🇸

Marlette, Michigan, United States

McLaren Cancer Institute-Macomb

🇺🇸

Mount Clemens, Michigan, United States

Trinity Health Saint Mary Mercy Livonia Hospital

🇺🇸

Livonia, Michigan, United States

Great Lakes Cancer Management Specialists-Macomb Medical Campus

🇺🇸

Macomb, Michigan, United States

Michigan Breast Specialists-Macomb Township

🇺🇸

Macomb, Michigan, United States

McLaren Cancer Institute-Central Michigan

🇺🇸

Mount Pleasant, Michigan, United States

Ascension Providence Hospitals - Novi

🇺🇸

Novi, Michigan, United States

McLaren Cancer Institute-Northern Michigan

🇺🇸

Petoskey, Michigan, United States

Newland Medical Associates-Pontiac

🇺🇸

Pontiac, Michigan, United States

Trinity Health Saint Joseph Mercy Oakland Hospital

🇺🇸

Pontiac, Michigan, United States

McLaren-Port Huron

🇺🇸

Port Huron, Michigan, United States

Great Lakes Cancer Management Specialists-Rochester Hills

🇺🇸

Rochester Hills, Michigan, United States

Corewell Health William Beaumont University Hospital

🇺🇸

Royal Oak, Michigan, United States

MyMichigan Medical Center Saginaw

🇺🇸

Saginaw, Michigan, United States

Oncology Hematology Associates of Saginaw Valley PC

🇺🇸

Saginaw, Michigan, United States

Ascension Providence Hospitals - Southfield

🇺🇸

Southfield, Michigan, United States

Bhadresh Nayak MD PC-Sterling Heights

🇺🇸

Sterling Heights, Michigan, United States

MyMichigan Medical Center Tawas

🇺🇸

Tawas City, Michigan, United States

Munson Medical Center

🇺🇸

Traverse City, Michigan, United States

Corewell Health Beaumont Troy Hospital

🇺🇸

Troy, Michigan, United States

Great Lakes Cancer Management Specialists-Macomb Professional Building

🇺🇸

Warren, Michigan, United States

Michigan Breast Specialists-Warren

🇺🇸

Warren, Michigan, United States

Saint John Macomb-Oakland Hospital

🇺🇸

Warren, Michigan, United States

Saint Mary's Oncology/Hematology Associates of West Branch

🇺🇸

West Branch, Michigan, United States

University of Michigan Health - West

🇺🇸

Wyoming, Michigan, United States

Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus

🇺🇸

Ypsilanti, Michigan, United States

Sanford Joe Lueken Cancer Center

🇺🇸

Bemidji, Minnesota, United States

Essentia Health Saint Joseph's Medical Center

🇺🇸

Brainerd, Minnesota, United States

Fairview Ridges Hospital

🇺🇸

Burnsville, Minnesota, United States

Essentia Health - Deer River Clinic

🇺🇸

Deer River, Minnesota, United States

Essentia Health Cancer Center

🇺🇸

Duluth, Minnesota, United States

Unity Hospital

🇺🇸

Fridley, Minnesota, United States

Abbott-Northwestern Hospital

🇺🇸

Minneapolis, Minnesota, United States

Hennepin County Medical Center

🇺🇸

Minneapolis, Minnesota, United States

Essentia Health Hibbing Clinic

🇺🇸

Hibbing, Minnesota, United States

Fairview Clinics and Surgery Center Maple Grove

🇺🇸

Maple Grove, Minnesota, United States

Mayo Clinic in Rochester

🇺🇸

Rochester, Minnesota, United States

Coborn Cancer Center at Saint Cloud Hospital

🇺🇸

Saint Cloud, Minnesota, United States

Park Nicollet Clinic - Saint Louis Park

🇺🇸

Saint Louis Park, Minnesota, United States

Regions Hospital

🇺🇸

Saint Paul, Minnesota, United States

United Hospital

🇺🇸

Saint Paul, Minnesota, United States

Essentia Health Sandstone

🇺🇸

Sandstone, Minnesota, United States

Sanford Thief River Falls Medical Center

🇺🇸

Thief River Falls, Minnesota, United States

Essentia Health Virginia Clinic

🇺🇸

Virginia, Minnesota, United States

Ridgeview Medical Center

🇺🇸

Waconia, Minnesota, United States

Baptist Memorial Hospital and Cancer Center-Golden Triangle

🇺🇸

Columbus, Mississippi, United States

Gulfport Memorial Hospital

🇺🇸

Gulfport, Mississippi, United States

Baptist Memorial Hospital and Cancer Center-Desoto

🇺🇸

Southhaven, Mississippi, United States

Parkland Health Center-Bonne Terre

🇺🇸

Bonne Terre, Missouri, United States

Saint Francis Medical Center

🇺🇸

Cape Girardeau, Missouri, United States

MU Health - University Hospital/Ellis Fischel Cancer Center

🇺🇸

Columbia, Missouri, United States

Siteman Cancer Center at West County Hospital

🇺🇸

Creve Coeur, Missouri, United States

Freeman Health System

🇺🇸

Joplin, Missouri, United States

Parkland Health Center - Farmington

🇺🇸

Farmington, Missouri, United States

MU Health Care Goldschmidt Cancer Center

🇺🇸

Jefferson City, Missouri, United States

University Health Truman Medical Center

🇺🇸

Kansas City, Missouri, United States

UHHS-Westlake Medical Center

🇺🇸

Westlake, Ohio, United States

University of Kansas Cancer Center - North

🇺🇸

Kansas City, Missouri, United States

University of Kansas Cancer Center - Lee's Summit

🇺🇸

Lee's Summit, Missouri, United States

University of Kansas Cancer Center at North Kansas City Hospital

🇺🇸

North Kansas City, Missouri, United States

Heartland Regional Medical Center

🇺🇸

Saint Joseph, Missouri, United States

Washington University School of Medicine

🇺🇸

Saint Louis, Missouri, United States

Siteman Cancer Center-South County

🇺🇸

Saint Louis, Missouri, United States

Missouri Baptist Medical Center

🇺🇸

Saint Louis, Missouri, United States

Siteman Cancer Center at Christian Hospital

🇺🇸

Saint Louis, Missouri, United States

Mercy Hospital Saint Louis

🇺🇸

Saint Louis, Missouri, United States

Siteman Cancer Center at Saint Peters Hospital

🇺🇸

Saint Peters, Missouri, United States

Sainte Genevieve County Memorial Hospital

🇺🇸

Sainte Genevieve, Missouri, United States

Missouri Baptist Sullivan Hospital

🇺🇸

Sullivan, Missouri, United States

Cancer Partners of Nebraska - Pine Lake

🇺🇸

Lincoln, Nebraska, United States

BJC Outpatient Center at Sunset Hills

🇺🇸

Sunset Hills, Missouri, United States

Billings Clinic Cancer Center

🇺🇸

Billings, Montana, United States

Bozeman Health Deaconess Hospital

🇺🇸

Bozeman, Montana, United States

Kalispell Regional Medical Center

🇺🇸

Kalispell, Montana, United States

Nebraska Cancer Specialists/Oncology Hematology West PC

🇺🇸

Grand Island, Nebraska, United States

Cancer Partners of Nebraska

🇺🇸

Lincoln, Nebraska, United States

Nebraska Methodist Hospital

🇺🇸

Omaha, Nebraska, United States

Alegent Health Bergan Mercy Medical Center

🇺🇸

Omaha, Nebraska, United States

OptumCare Cancer Care at Charleston

🇺🇸

Las Vegas, Nevada, United States

OptumCare Cancer Care at MountainView

🇺🇸

Las Vegas, Nevada, United States

Comprehensive Cancer Centers of Nevada

🇺🇸

Las Vegas, Nevada, United States

OptumCare Cancer Care at Fort Apache

🇺🇸

Las Vegas, Nevada, United States

New Hampshire Oncology Hematology PA-Concord

🇺🇸

Concord, New Hampshire, United States

Solinsky Center for Cancer Care

🇺🇸

Manchester, New Hampshire, United States

Exeter Hospital

🇺🇸

Exeter, New Hampshire, United States

Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center

🇺🇸

Lebanon, New Hampshire, United States

Memorial Sloan Kettering Basking Ridge

🇺🇸

Basking Ridge, New Jersey, United States

Cooper Hospital University Medical Center

🇺🇸

Camden, New Jersey, United States

Hackensack University Medical Center

🇺🇸

Hackensack, New Jersey, United States

Memorial Sloan Kettering Monmouth

🇺🇸

Middletown, New Jersey, United States

Memorial Sloan Kettering Bergen

🇺🇸

Montvale, New Jersey, United States

The Valley Hospital - Luckow Pavilion

🇺🇸

Paramus, New Jersey, United States

Neurosurgeons of New Jersey-Ridgewood

🇺🇸

Ridgewood, New Jersey, United States

Valley Health System Ridgewood Campus

🇺🇸

Ridgewood, New Jersey, United States

Valley Medical Group - Wayne Multispecialty Practice

🇺🇸

Wayne, New Jersey, United States

Holy Name Hospital

🇺🇸

Teaneck, New Jersey, United States

MD Anderson Cancer Center at Cooper-Voorhees

🇺🇸

Voorhees, New Jersey, United States

Valley Health System-Hematology/Oncology

🇺🇸

Westwood, New Jersey, United States

Presbyterian Rust Medical Center/Jorgensen Cancer Center

🇺🇸

Rio Rancho, New Mexico, United States

Hematology Oncology Associates of Central New York-Auburn

🇺🇸

Auburn, New York, United States

University of New Mexico Cancer Center

🇺🇸

Albuquerque, New Mexico, United States

Montefiore Medical Center-Einstein Campus

🇺🇸

Bronx, New York, United States

New Mexico Oncology Hematology Consultants

🇺🇸

Albuquerque, New Mexico, United States

Presbyterian Kaseman Hospital

🇺🇸

Albuquerque, New Mexico, United States

Memorial Medical Center - Las Cruces

🇺🇸

Las Cruces, New Mexico, United States

Montefiore Medical Center-Weiler Hospital

🇺🇸

Bronx, New York, United States

Hematology Oncology Associates of Central New York-East Syracuse

🇺🇸

East Syracuse, New York, United States

Montefiore Medical Center - Moses Campus

🇺🇸

Bronx, New York, United States

Roswell Park Cancer Institute

🇺🇸

Buffalo, New York, United States

Hematology Oncology Associates of CNY at Camillus

🇺🇸

Camillus, New York, United States

Memorial Sloan Kettering Commack

🇺🇸

Commack, New York, United States

Memorial Sloan Kettering Westchester

🇺🇸

Harrison, New York, United States

NYU Langone Hospital - Long Island

🇺🇸

Mineola, New York, United States

Mount Sinai Union Square

🇺🇸

New York, New York, United States

Mount Sinai West

🇺🇸

New York, New York, United States

Stony Brook University Medical Center

🇺🇸

Stony Brook, New York, United States

State University of New York Upstate Medical University

🇺🇸

Syracuse, New York, United States

Mount Sinai Hospital

🇺🇸

New York, New York, United States

Memorial Sloan Kettering Cancer Center

🇺🇸

New York, New York, United States

University of Rochester

🇺🇸

Rochester, New York, United States

Memorial Sloan Kettering Nassau

🇺🇸

Uniondale, New York, United States

Good Samaritan University Hospital

🇺🇸

West Islip, New York, United States

Atrium Health Stanly/LCI-Albemarle

🇺🇸

Albemarle, North Carolina, United States

Randolph Hospital

🇺🇸

Asheboro, North Carolina, United States

Mission Hospital

🇺🇸

Asheville, North Carolina, United States

AdventHealth Infusion Center Asheville

🇺🇸

Asheville, North Carolina, United States

Messino Cancer Centers

🇺🇸

Asheville, North Carolina, United States

Hope Women's Cancer Centers-Asheville

🇺🇸

Asheville, North Carolina, United States

Cone Health Cancer Center at Alamance Regional

🇺🇸

Burlington, North Carolina, United States

Carolinas Medical Center/Levine Cancer Institute

🇺🇸

Charlotte, North Carolina, United States

Atrium Health Pineville/LCI-Pineville

🇺🇸

Charlotte, North Carolina, United States

Southeastern Medical Oncology Center-Clinton

🇺🇸

Clinton, North Carolina, United States

AdventHealth Infusion Center Haywood

🇺🇸

Clyde, North Carolina, United States

Atrium Health Cabarrus/LCI-Concord

🇺🇸

Concord, North Carolina, United States

Levine Cancer Institute-Gaston

🇺🇸

Gastonia, North Carolina, United States

Southeastern Medical Oncology Center-Goldsboro

🇺🇸

Goldsboro, North Carolina, United States

Cone Health Cancer Center

🇺🇸

Greensboro, North Carolina, United States

Margaret R Pardee Memorial Hospital

🇺🇸

Hendersonville, North Carolina, United States

AdventHealth Hendersonville

🇺🇸

Hendersonville, North Carolina, United States

Southeastern Medical Oncology Center-Jacksonville

🇺🇸

Jacksonville, North Carolina, United States

ECU Health Oncology Kenansville

🇺🇸

Kenansville, North Carolina, United States

ECU Health Oncology Kinston

🇺🇸

Kinston, North Carolina, United States

Atrium Health Lincoln/LCI-Lincolnton

🇺🇸

Lincolnton, North Carolina, United States

Cone Heath Cancer Center at Mebane

🇺🇸

Mebane, North Carolina, United States

FirstHealth of the Carolinas-Moore Regional Hospital

🇺🇸

Pinehurst, North Carolina, United States

ECU Health Oncology Richlands

🇺🇸

Richlands, North Carolina, United States

Nash UNC HealthCare

🇺🇸

Rocky Mount, North Carolina, United States

Marion L Shepard Cancer Center - ECU Health Beaufort Hospital

🇺🇸

Washington, North Carolina, United States

Wake Forest University Health Sciences

🇺🇸

Winston-Salem, North Carolina, United States

Sanford Bismarck Medical Center

🇺🇸

Bismarck, North Dakota, United States

Sanford Broadway Medical Center

🇺🇸

Fargo, North Dakota, United States

Sanford Roger Maris Cancer Center

🇺🇸

Fargo, North Dakota, United States

Summa Health System - Barberton Campus

🇺🇸

Barberton, Ohio, United States

Summa Health System - Akron Campus

🇺🇸

Akron, Ohio, United States

UHHS-Chagrin Highlands Medical Center

🇺🇸

Beachwood, Ohio, United States

Strecker Cancer Center-Belpre

🇺🇸

Belpre, Ohio, United States

Geauga Hospital

🇺🇸

Chardon, Ohio, United States

Cleveland Clinic Mercy Hospital

🇺🇸

Canton, Ohio, United States

Adena Regional Medical Center

🇺🇸

Chillicothe, Ohio, United States

University of Cincinnati Cancer Center-UC Medical Center

🇺🇸

Cincinnati, Ohio, United States

Good Samaritan Hospital - Cincinnati

🇺🇸

Cincinnati, Ohio, United States

Case Western Reserve University

🇺🇸

Cleveland, Ohio, United States

MetroHealth Medical Center

🇺🇸

Cleveland, Ohio, United States

Cleveland Clinic Cancer Center/Fairview Hospital

🇺🇸

Cleveland, Ohio, United States

Cleveland Clinic Foundation

🇺🇸

Cleveland, Ohio, United States

Ohio State University Comprehensive Cancer Center

🇺🇸

Columbus, Ohio, United States

Mount Carmel East Hospital

🇺🇸

Columbus, Ohio, United States

Columbus Oncology and Hematology Associates Inc

🇺🇸

Columbus, Ohio, United States

Riverside Methodist Hospital

🇺🇸

Columbus, Ohio, United States

Grant Medical Center

🇺🇸

Columbus, Ohio, United States

The Mark H Zangmeister Center

🇺🇸

Columbus, Ohio, United States

Mount Carmel Health Center West

🇺🇸

Columbus, Ohio, United States

Doctors Hospital

🇺🇸

Columbus, Ohio, United States

Dayton Physician LLC - Englewood

🇺🇸

Dayton, Ohio, United States

Delaware Health Center-Grady Cancer Center

🇺🇸

Delaware, Ohio, United States

Grady Memorial Hospital

🇺🇸

Delaware, Ohio, United States

Mercy Cancer Center-Elyria

🇺🇸

Elyria, Ohio, United States

Fairfield Medical Center

🇺🇸

Lancaster, Ohio, United States

OhioHealth Mansfield Hospital

🇺🇸

Mansfield, Ohio, United States

Cleveland Clinic Cancer Center Mansfield

🇺🇸

Mansfield, Ohio, United States

Marietta Memorial Hospital

🇺🇸

Marietta, Ohio, United States

OhioHealth Marion General Hospital

🇺🇸

Marion, Ohio, United States

Hillcrest Hospital Cancer Center

🇺🇸

Mayfield Heights, Ohio, United States

UH Seidman Cancer Center at Lake Health Mentor Campus

🇺🇸

Mentor, Ohio, United States

UH Seidman Cancer Center at Southwest General Hospital

🇺🇸

Middleburg Heights, Ohio, United States

Summa Health Medina Medical Center

🇺🇸

Medina, Ohio, United States

Knox Community Hospital

🇺🇸

Mount Vernon, Ohio, United States

Licking Memorial Hospital

🇺🇸

Newark, Ohio, United States

University Hospitals Parma Medical Center

🇺🇸

Parma, Ohio, United States

Southern Ohio Medical Center

🇺🇸

Portsmouth, Ohio, United States

University Hospitals Portage Medical Center

🇺🇸

Ravenna, Ohio, United States

North Coast Cancer Care

🇺🇸

Sandusky, Ohio, United States

UH Seidman Cancer Center at Firelands Regional Medical Center

🇺🇸

Sandusky, Ohio, United States

Cleveland Clinic Cancer Center Strongsville

🇺🇸

Strongsville, Ohio, United States

ProMedica Flower Hospital

🇺🇸

Sylvania, Ohio, United States

University Hospitals Sharon Health Center

🇺🇸

Wadsworth, Ohio, United States

South Pointe Hospital

🇺🇸

Warrensville Heights, Ohio, United States

University of Cincinnati Cancer Center-West Chester

🇺🇸

West Chester, Ohio, United States

Saint Ann's Hospital

🇺🇸

Westerville, Ohio, United States

UH Seidman Cancer Center at Saint John Medical Center

🇺🇸

Westlake, Ohio, United States

Cleveland Clinic Wooster Family Health and Surgery Center

🇺🇸

Wooster, Ohio, United States

Genesis Healthcare System Cancer Care Center

🇺🇸

Zanesville, Ohio, United States

Cancer Centers of Southwest Oklahoma Research

🇺🇸

Lawton, Oklahoma, United States

University of Oklahoma Health Sciences Center

🇺🇸

Oklahoma City, Oklahoma, United States

Mercy Hospital Oklahoma City

🇺🇸

Oklahoma City, Oklahoma, United States

Integris Cancer Institute of Oklahoma

🇺🇸

Oklahoma City, Oklahoma, United States

Integris Southwest Medical Center

🇺🇸

Oklahoma City, Oklahoma, United States

Cancer Treatment Centers of America

🇺🇸

Tulsa, Oklahoma, United States

Oklahoma Cancer Specialists and Research Institute-Tulsa

🇺🇸

Tulsa, Oklahoma, United States

Providence Cancer Institute Clackamas Clinic

🇺🇸

Clackamas, Oregon, United States

Saint Alphonsus Cancer Care Center-Ontario

🇺🇸

Ontario, Oregon, United States

Providence Portland Medical Center

🇺🇸

Portland, Oregon, United States

Providence Newberg Medical Center

🇺🇸

Newberg, Oregon, United States

Providence Saint Vincent Medical Center

🇺🇸

Portland, Oregon, United States

Saint Luke's University Hospital-Bethlehem Campus

🇺🇸

Bethlehem, Pennsylvania, United States

Crozer-Keystone Regional Cancer Center at Broomall

🇺🇸

Broomall, Pennsylvania, United States

Bryn Mawr Hospital

🇺🇸

Bryn Mawr, Pennsylvania, United States

Main Line Health Center-Collegeville

🇺🇸

Collegeville, Pennsylvania, United States

Geisinger Medical Center

🇺🇸

Danville, Pennsylvania, United States

Delaware County Memorial Hospital

🇺🇸

Drexel Hill, Pennsylvania, United States

Saint Vincent Hospital

🇺🇸

Erie, Pennsylvania, United States

Main Line Health Center-Exton

🇺🇸

Exton, Pennsylvania, United States

Crozer Regional Cancer Center at Brinton Lake

🇺🇸

Glen Mills, Pennsylvania, United States

UPMC Cancer Centers - Arnold Palmer Pavilion

🇺🇸

Greensburg, Pennsylvania, United States

Virginia Cancer Institute

🇺🇸

Richmond, Virginia, United States

UPMC Pinnacle Cancer Center/Community Osteopathic Campus

🇺🇸

Harrisburg, Pennsylvania, United States

Geisinger Medical Center-Cancer Center Hazleton

🇺🇸

Hazleton, Pennsylvania, United States

Penn State Milton S Hershey Medical Center

🇺🇸

Hershey, Pennsylvania, United States

Jefferson Hospital

🇺🇸

Jefferson Hills, Pennsylvania, United States

UPMC-Johnstown/John P. Murtha Regional Cancer Center

🇺🇸

Johnstown, Pennsylvania, United States

Lancaster General Ann B Barshinger Cancer Institute

🇺🇸

Lancaster, Pennsylvania, United States

Lancaster General Hospital

🇺🇸

Lancaster, Pennsylvania, United States

Geisinger Medical Oncology-Lewisburg

🇺🇸

Lewisburg, Pennsylvania, United States

Redeemer Health

🇺🇸

Meadowbrook, Pennsylvania, United States

Riddle Memorial Hospital

🇺🇸

Media, Pennsylvania, United States

Forbes Hospital

🇺🇸

Monroeville, Pennsylvania, United States

Paoli Memorial Hospital

🇺🇸

Paoli, Pennsylvania, United States

Thomas Jefferson University Hospital

🇺🇸

Philadelphia, Pennsylvania, United States

Eastern Regional Medical Center

🇺🇸

Philadelphia, Pennsylvania, United States

Allegheny General Hospital

🇺🇸

Pittsburgh, Pennsylvania, United States

Guthrie Medical Group PC-Robert Packer Hospital

🇺🇸

Sayre, Pennsylvania, United States

Community Medical Center

🇺🇸

Scranton, Pennsylvania, United States

UPMC-Magee Womens Hospital

🇺🇸

Pittsburgh, Pennsylvania, United States

West Penn Hospital

🇺🇸

Pittsburgh, Pennsylvania, United States

University of Pittsburgh Cancer Institute (UPCI)

🇺🇸

Pittsburgh, Pennsylvania, United States

UPMC-Passavant Hospital

🇺🇸

Pittsburgh, Pennsylvania, United States

Geisinger Cancer Services-Pottsville

🇺🇸

Pottsville, Pennsylvania, United States

Crozer-Chester Medical Center

🇺🇸

Upland, Pennsylvania, United States

Reading Hospital

🇺🇸

West Reading, Pennsylvania, United States

Wexford Health and Wellness Pavilion

🇺🇸

Wexford, Pennsylvania, United States

Geisinger Wyoming Valley/Henry Cancer Center

🇺🇸

Wilkes-Barre, Pennsylvania, United States

UPMC Susquehanna

🇺🇸

Williamsport, Pennsylvania, United States

Asplundh Cancer Pavilion

🇺🇸

Willow Grove, Pennsylvania, United States

Prisma Health Cancer Institute - Easley

🇺🇸

Easley, South Carolina, United States

Lankenau Medical Center

🇺🇸

Wynnewood, Pennsylvania, United States

Saint Francis Hospital

🇺🇸

Greenville, South Carolina, United States

UPMC Memorial

🇺🇸

York, Pennsylvania, United States

Women and Infants Hospital

🇺🇸

Providence, Rhode Island, United States

Saint Joseph's/Candler - Bluffton Campus

🇺🇸

Bluffton, South Carolina, United States

Prisma Health Cancer Institute - Spartanburg

🇺🇸

Boiling Springs, South Carolina, United States

Medical University of South Carolina

🇺🇸

Charleston, South Carolina, United States

Prisma Health Cancer Institute - Butternut

🇺🇸

Greenville, South Carolina, United States

Prisma Health Cancer Institute - Faris

🇺🇸

Greenville, South Carolina, United States

Saint Francis Cancer Center

🇺🇸

Greenville, South Carolina, United States

Prisma Health Cancer Institute - Eastside

🇺🇸

Greenville, South Carolina, United States

Prisma Health Cancer Institute - Greer

🇺🇸

Greer, South Carolina, United States

Gibbs Cancer Center-Pelham

🇺🇸

Greer, South Carolina, United States

South Carolina Cancer Specialists PC

🇺🇸

Hilton Head Island, South Carolina, United States

Levine Cancer Institute-Rock Hill

🇺🇸

Rock Hill, South Carolina, United States

Prisma Health Cancer Institute - Seneca

🇺🇸

Seneca, South Carolina, United States

Spartanburg Medical Center

🇺🇸

Spartanburg, South Carolina, United States

Lexington Medical Center

🇺🇸

West Columbia, South Carolina, United States

Avera Cancer Institute-Aberdeen

🇺🇸

Aberdeen, South Dakota, United States

Sanford Cancer Center Oncology Clinic

🇺🇸

Sioux Falls, South Dakota, United States

Aurora Cancer Care-Grafton

🇺🇸

Grafton, Wisconsin, United States

Avera Cancer Institute

🇺🇸

Sioux Falls, South Dakota, United States

Sanford USD Medical Center - Sioux Falls

🇺🇸

Sioux Falls, South Dakota, United States

Baptist Memorial Hospital and Cancer Center-Collierville

🇺🇸

Collierville, Tennessee, United States

Cookeville Regional Medical Center

🇺🇸

Cookeville, Tennessee, United States

Ballad Health Cancer Care - Kingsport

🇺🇸

Kingsport, Tennessee, United States

Thompson Cancer Survival Center

🇺🇸

Knoxville, Tennessee, United States

Thompson Cancer Survival Center - West

🇺🇸

Knoxville, Tennessee, United States

Thompson Oncology Group-Lenoir City

🇺🇸

Lenoir City, Tennessee, United States

Thompson Oncology Group-Maryville

🇺🇸

Maryville, Tennessee, United States

Baptist Memorial Hospital and Cancer Center-Memphis

🇺🇸

Memphis, Tennessee, United States

Thompson Oncology Group-Oak Ridge

🇺🇸

Oak Ridge, Tennessee, United States

Houston Methodist Hospital

🇺🇸

Houston, Texas, United States

M D Anderson Cancer Center

🇺🇸

Houston, Texas, United States

Doctor's Hospital of Laredo

🇺🇸

Laredo, Texas, United States

University of Texas Health Science Center at San Antonio

🇺🇸

San Antonio, Texas, United States

Wellmont Medical Associates-Bristol

🇺🇸

Bristol, Virginia, United States

Huntsman Cancer Institute/University of Utah

🇺🇸

Salt Lake City, Utah, United States

Kaiser Permanente-Burke Medical Center

🇺🇸

Burke, Virginia, United States

Inova Schar Cancer Institute

🇺🇸

Fairfax, Virginia, United States

Kaiser Permanente Tysons Corner Medical Center

🇺🇸

McLean, Virginia, United States

Bon Secours Memorial Regional Medical Center

🇺🇸

Mechanicsville, Virginia, United States

Bon Secours Saint Francis Medical Center

🇺🇸

Midlothian, Virginia, United States

Southwest VA Regional Cancer Center

🇺🇸

Norton, Virginia, United States

Bon Secours Saint Mary's Hospital

🇺🇸

Richmond, Virginia, United States

VCU Massey Cancer Center at Stony Point

🇺🇸

Richmond, Virginia, United States

Virginia Commonwealth University/Massey Cancer Center

🇺🇸

Richmond, Virginia, United States

VCU Community Memorial Health Center

🇺🇸

South Hill, Virginia, United States

Shenandoah Oncology PC

🇺🇸

Winchester, Virginia, United States

MultiCare Auburn Medical Center

🇺🇸

Auburn, Washington, United States

Swedish Cancer Institute-Edmonds

🇺🇸

Edmonds, Washington, United States

Providence Regional Cancer Partnership

🇺🇸

Everett, Washington, United States

Swedish Cancer Institute-Issaquah

🇺🇸

Issaquah, Washington, United States

MultiCare Gig Harbor Medical Park

🇺🇸

Gig Harbor, Washington, United States

MultiCare Good Samaritan Hospital

🇺🇸

Puyallup, Washington, United States

Swedish Medical Center-First Hill

🇺🇸

Seattle, Washington, United States

MultiCare Deaconess Cancer and Blood Specialty Center - Valley

🇺🇸

Spokane Valley, Washington, United States

MultiCare Deaconess Cancer and Blood Specialty Center - North

🇺🇸

Spokane, Washington, United States

MultiCare Deaconess Cancer and Blood Specialty Center - Downtown

🇺🇸

Spokane, Washington, United States

MultiCare Tacoma General Hospital

🇺🇸

Tacoma, Washington, United States

United Hospital Center

🇺🇸

Bridgeport, West Virginia, United States

West Virginia University Charleston Division

🇺🇸

Charleston, West Virginia, United States

West Virginia University Healthcare

🇺🇸

Morgantown, West Virginia, United States

Camden Clark Medical Center

🇺🇸

Parkersburg, West Virginia, United States

Langlade Hospital and Cancer Center

🇺🇸

Antigo, Wisconsin, United States

ThedaCare Regional Cancer Center

🇺🇸

Appleton, Wisconsin, United States

Duluth Clinic Ashland

🇺🇸

Ashland, Wisconsin, United States

Aurora Cancer Care-Southern Lakes VLCC

🇺🇸

Burlington, Wisconsin, United States

Marshfield Medical Center-EC Cancer Center

🇺🇸

Eau Claire, Wisconsin, United States

Mayo Clinic Health System-Eau Claire Clinic

🇺🇸

Eau Claire, Wisconsin, United States

Aurora Health Care Germantown Health Center

🇺🇸

Germantown, Wisconsin, United States

Saint Vincent Hospital Cancer Center Green Bay

🇺🇸

Green Bay, Wisconsin, United States

Saint Vincent Hospital Cancer Center at Saint Mary's

🇺🇸

Green Bay, Wisconsin, United States

Aurora BayCare Medical Center

🇺🇸

Green Bay, Wisconsin, United States

Mercyhealth Hospital and Cancer Center - Janesville

🇺🇸

Janesville, Wisconsin, United States

University of Wisconsin Carbone Cancer Center - Johnson Creek

🇺🇸

Johnson Creek, Wisconsin, United States

Aurora Cancer Care-Kenosha South

🇺🇸

Kenosha, Wisconsin, United States

Mayo Clinic Health System-Franciscan Healthcare

🇺🇸

La Crosse, Wisconsin, United States

SSM Health Dean Medical Group - South Madison Campus

🇺🇸

Madison, Wisconsin, United States

University of Wisconsin Carbone Cancer Center - University Hospital

🇺🇸

Madison, Wisconsin, United States

Marshfield Medical Center-Marshfield

🇺🇸

Marshfield, Wisconsin, United States

Aurora Bay Area Medical Group-Marinette

🇺🇸

Marinette, Wisconsin, United States

Saint Vincent Hospital Cancer Center at Marinette

🇺🇸

Marinette, Wisconsin, United States

Aspirus Medford Hospital

🇺🇸

Medford, Wisconsin, United States

Aurora Cancer Care-Milwaukee

🇺🇸

Milwaukee, Wisconsin, United States

Aurora Saint Luke's Medical Center

🇺🇸

Milwaukee, Wisconsin, United States

Aurora Sinai Medical Center

🇺🇸

Milwaukee, Wisconsin, United States

Marshfield Clinic-Minocqua Center

🇺🇸

Minocqua, Wisconsin, United States

ProHealth D N Greenwald Center

🇺🇸

Mukwonago, Wisconsin, United States

ThedaCare Regional Medical Center - Neenah

🇺🇸

Neenah, Wisconsin, United States

ProHealth Oconomowoc Memorial Hospital

🇺🇸

Oconomowoc, Wisconsin, United States

Saint Vincent Hospital Cancer Center at Oconto Falls

🇺🇸

Oconto Falls, Wisconsin, United States

Vince Lombardi Cancer Clinic - Oshkosh

🇺🇸

Oshkosh, Wisconsin, United States

Aurora Cancer Care-Racine

🇺🇸

Racine, Wisconsin, United States

Marshfield Medical Center-Rice Lake

🇺🇸

Rice Lake, Wisconsin, United States

Vince Lombardi Cancer Clinic-Sheboygan

🇺🇸

Sheboygan, Wisconsin, United States

Marshfield Medical Center-River Region at Stevens Point

🇺🇸

Stevens Point, Wisconsin, United States

Saint Vincent Hospital Cancer Center at Sturgeon Bay

🇺🇸

Sturgeon Bay, Wisconsin, United States

Aurora Medical Center in Summit

🇺🇸

Summit, Wisconsin, United States

Vince Lombardi Cancer Clinic-Two Rivers

🇺🇸

Two Rivers, Wisconsin, United States

ProHealth Waukesha Memorial Hospital

🇺🇸

Waukesha, Wisconsin, United States

UW Cancer Center at ProHealth Care

🇺🇸

Waukesha, Wisconsin, United States

Aspirus Regional Cancer Center

🇺🇸

Wausau, Wisconsin, United States

Aurora Cancer Care-Milwaukee West

🇺🇸

Wauwatosa, Wisconsin, United States

Aurora West Allis Medical Center

🇺🇸

West Allis, Wisconsin, United States

Marshfield Medical Center - Weston

🇺🇸

Weston, Wisconsin, United States

Aspirus Cancer Care - Wisconsin Rapids

🇺🇸

Wisconsin Rapids, Wisconsin, United States

Cross Cancer Institute

🇨🇦

Edmonton, Alberta, Canada

BCCA-Vancouver Cancer Centre

🇨🇦

Vancouver, British Columbia, Canada

BCCA-Vancouver Island Cancer Centre

🇨🇦

Victoria, British Columbia, Canada

The Moncton Hospital

🇨🇦

Moncton, New Brunswick, Canada

Doctor H. Bliss Murphy Cancer Centre

🇨🇦

St. John's, Newfoundland and Labrador, Canada

William Osler Health System-Brampton Civic Hospital

🇨🇦

Brampton, Ontario, Canada

London Regional Cancer Program

🇨🇦

London, Ontario, Canada

Algoma District Cancer Program Sault Area Hospital

🇨🇦

Sault Ste Marie, Ontario, Canada

University Health Network-Princess Margaret Hospital

🇨🇦

Toronto, Ontario, Canada

CSSS Champlain-Charles Le Moyne

🇨🇦

Greenfield Park, Quebec, Canada

Allan Blair Cancer Centre

🇨🇦

Regina, Saskatchewan, Canada

Related Trials

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy